S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

CAN-FITE BIOPHA/S Stock Price, Forecast & Analysis (NYSEAMERICAN:CANF)

$2.37
-0.05 (-2.07 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$2.28
Now: $2.37
$2.38
50-Day Range N/A
52-Week Range
$1.90
Now: $2.37
$25.95
Volume41,500 shs
Average Volume181,060 shs
Market Capitalization$3.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CANF
CUSIPN/A
Phone+972-3-9241114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$3.16 million
Next Earnings Date11/29/2019 (Estimated)
OptionableOptionable

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.


CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) Frequently Asked Questions

What is CAN-FITE BIOPHA/S's stock symbol?

CAN-FITE BIOPHA/S trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How were CAN-FITE BIOPHA/S's earnings last quarter?

CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) issued its earnings results on Friday, August, 30th. The biotechnology company reported ($1.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.80) by $0.40. The biotechnology company earned $0.39 million during the quarter. View CAN-FITE BIOPHA/S's Earnings History.

When is CAN-FITE BIOPHA/S's next earnings date?

CAN-FITE BIOPHA/S is scheduled to release their next quarterly earnings announcement on Friday, November 29th 2019. View Earnings Estimates for CAN-FITE BIOPHA/S.

What price target have analysts set for CANF?

1 brokers have issued 1-year price objectives for CAN-FITE BIOPHA/S's stock. Their forecasts range from $5.00 to $5.00. On average, they expect CAN-FITE BIOPHA/S's stock price to reach $5.00 in the next year. This suggests a possible upside of 111.0% from the stock's current price. View Analyst Price Targets for CAN-FITE BIOPHA/S.

What is the consensus analysts' recommendation for CAN-FITE BIOPHA/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CAN-FITE BIOPHA/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CAN-FITE BIOPHA/S.

What are Wall Street analysts saying about CAN-FITE BIOPHA/S stock?

Here are some recent quotes from research analysts about CAN-FITE BIOPHA/S stock:
  • 1. According to Zacks Investment Research, "Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel. " (10/4/2019)
  • 2. HC Wainwright analysts commented, "We reiterate our Buy rating and 12-month price target (PT) of $3. Our PT was derived by using a 25% rate to discount free cash flows from annual sales and royalty payments of piclidenoson in RA and psoriasis for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 65% clinical program probability of success." (3/27/2019)

Has CAN-FITE BIOPHA/S been receiving favorable news coverage?

Press coverage about CANF stock has been trending positive on Wednesday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CAN-FITE BIOPHA/S earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for CAN-FITE BIOPHA/S.

Who are some of CAN-FITE BIOPHA/S's key competitors?

What other stocks do shareholders of CAN-FITE BIOPHA/S own?

Who are CAN-FITE BIOPHA/S's key executives?

CAN-FITE BIOPHA/S's management team includes the folowing people:
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 65)
  • Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 71)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 55)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 47)
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

How do I buy shares of CAN-FITE BIOPHA/S?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CAN-FITE BIOPHA/S's stock price today?

One share of CANF stock can currently be purchased for approximately $2.37.

How big of a company is CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S has a market capitalization of $3.16 million. CAN-FITE BIOPHA/S employs 7 workers across the globe.View Additional Information About CAN-FITE BIOPHA/S.

What is CAN-FITE BIOPHA/S's official website?

The official website for CAN-FITE BIOPHA/S is http://www.canfite.co.il/.

How can I contact CAN-FITE BIOPHA/S?

CAN-FITE BIOPHA/S's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.


MarketBeat Community Rating for CAN-FITE BIOPHA/S (NYSEAMERICAN CANF)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about CAN-FITE BIOPHA/S and other stocks. Vote "Outperform" if you believe CANF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CANF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: What is the Current Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel